CAAR ruled that multi-functional PCR instruments cannot be treated as spectrometers where optical detection is only one part ...
Qiagen N.V. (NYSE:QGEN) ranks among the best CRISPR stocks to buy. Qiagen N.V. (NYSE:QGEN) and Gencurix announced a collaboration on June 18 to provide oncology assays for Qiagen’s QIAcuityDx digital ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a ...
VENLO, Netherlands, June 18, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays ...
Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic laboratories a range of clinical oncology assays VENLO, Netherlands ...
On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction ...
VENLO, Netherlands–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) ...
VENLO, the Netherlands–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) ...
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback